Reimbursement,
20.07.2020
DiGA consultation meetings: Prescription and use
What we took from the last online meeting with the hih of the Federal Ministry of Health? Here is a short and concise summary:
The BfArM has held consultation meetings with about 50 DiGA manufacturers and received 14 applications for inclusion in the DiGA directory (as of 16.07.20). At the end of August 2020, the first DiGAs that are listed in the directory can be expected. For the time being, the ordinance will be based on "Muster 16"; the basis for use and invoicing will be a 16-digit prescription code. Price negotiations will be held between the manufacturer and the GKV-SV after successful #evaluation. Relevant principles on pricing and remuneration are regulated in the framework agreement and billing guidelines.
More information is available at in our German speaking sites.
Market Access,
10.06.2020
With the Digital Care Act (DVG), structures were created to establish regular reimbursement for digital health applications (DiGA) in Germany. What evidence is necessary to convince the Federal Institute for Drugs and Medical Devices (BfArM)? How do I effectively conduct a consultation with the authority and what are the minimum requirements for an evaluation concept? We answer these and other questions based on our first experiences with the new regulations and, if necessary, we will be happy to network with our customers. Request a catalogue of criteria and further practical informatio or learn more on DiGA in the German market
Real World Evidence, Evidence Generation
11.02.2021
A brief video summary of our latest study using a Discrete Choice Experiment (DCE); health services research:
Use our smart tools to efficiently enter the German speaking (D-A-CH) market.
Introduce and keep competitive prices.
Modern ways to generate evidence.
Prevalence of #atopicdermatitis (AD) is estimated to be 2.19% in Germany, which translates to 1.53 million adults with AD in Germany. This is the result of an analysis of @LinkCareGmbH and Lilly for a Module 3 in the #AMNOG process for #Baricitinib #GBA https://t.co/BwAI5G5D2n
— LinkCare GmbH (@LinkCareGmbH) February 16, 2021
Hat Deutschland im internationalen Vergleich eine höhere Sterblichkeit bei #Sepsis und septischem Schock? In unserer neuen #Metanalyse ergaben sich keine Anhaltspunkte für eine erhöhte Sterblichkeit in Deutschland. https://t.co/YqQ1BrOPNq @Anaesthesisten @sepsisdialog @UKJ_Jena
— LinkCare GmbH (@LinkCareGmbH) February 11, 2021
Given a choice, which treatment options, oral or topical, would patients with peripheral polyneuropathic pain choose? Find out in the infographic of our latest publication. https://t.co/drzdF88l0J #polyneuropathicpain #discretechoiceexperiment #topicaltherapy #healtheconomics pic.twitter.com/cU46NmpilX
— LinkCare GmbH (@LinkCareGmbH) January 11, 2021
On 30.10. we presented our #epidemiology analysis of residual excessive daytime sleepiness (#EDS) at the #DGSM. Important findings: we have to assume that at least 34k patients in GER with #OSA and #CPAP therapy also have EDS. Every 2nd is unemployable and with psych. comorbidity
— LinkCare GmbH (@LinkCareGmbH) November 1, 2020
What may be relevant clinical differences in the prescription of #opioids for #chronic #backpain? we showed in coop. with an academic industry partnership at the Congress for #healthcareresearch #Versorgungsforschung that co-medication plays a major role. https://t.co/r49PXnTSPF
— LinkCare GmbH (@LinkCareGmbH) October 3, 2020
#Evaluation und Evidenzanforderungen für #DiGA: positiver Versorgungseffekt (pVE), was ist das und was Sie beachten sollten haben wir in unserem Blog für Sie zusammengefasst #appsaufrezept #medicalapp #DiGAV #Nutzenbewertung @bfarm_de @DigitalVersorgt https://t.co/XpyaXVXyJT
— LinkCare GmbH (@LinkCareGmbH) June 18, 2020